JP6416010B2 - Sulfur-containing amino acid and zinc-containing composition - Google Patents

Description

  The present invention relates to a composition containing S-1-propenyl-L-cysteine sulfoxide and zinc.

  In recent years, the aging of the population has further progressed, and improving the quality of life (QOL) of middle-aged and elderly men has become an issue. Male climacteric syndrome is a disease mainly caused by a decrease in the amount of male hormones associated with aging, and is sometimes called aging male hypogonadism syndrome (LOH syndrome). LOH syndrome is a syndrome whose main complaint is a physical or mental disorder caused by a decrease in the amount of male hormones due to aging. Symptoms of LOH syndrome include: 1) the quality and frequency of libido and erectile ability, especially a decrease in nighttime sleep erection; 2) intellectual activity, cognitive ability, poor orientation, and fatigue, depression, temperament 3) Sleep disorders; 4) Decreased lean body mass due to muscle capacity and weakness; 5) Increased visceral fat; 6) Changes in body hair and skin; 7) Bone associated with osteopenia and osteoporosis There is a decrease in salt and an increased risk of fractures. For the diagnosis of LOH syndrome, exclusion of other diseases by general clinical examination and differentiation by male hormone level test and interview (Aging male's symptoms (AMS) score by Heinemann et al.) Are performed.

  Testosterone, a male steroid hormone, is generally known to increase muscle mass. Testosterone replacement therapy is also used to treat male menopause syndrome. However, since steroid hormones such as testosterone have serious side effects, their administration requires careful management.

  In order to supplement testosterone more easily, foods such as natto, okra, yam, and sea cucumber, which are related to testosterone production, and supplements such as vitamin E and niacin are ingested. However, in order to increase testosterone, it is necessary to continuously ingest a large amount of the food or supplement, and there is a concern about side effects due to the excessive intake. Furthermore, increasing testosterone indirectly with foods and supplements often does not improve subjective symptoms. Most of the conventional foods and supplements for supplementing testosterone are not effective enough for practical use. Therefore, there is a need for the development of materials that can be safely ingested and that are effective in recovering the physical and mental QOL decline associated with male androgen depletion.

  The sulfur-containing amino acid is a general term for amino acids having a sulfur atom in the molecule. S-1-propenyl-L-cysteine sulfoxide (PCSO) is a kind of sulfur-containing amino acid having a sulfur atom as a sulfoxide, and is a precursor of the onion tearing component. When the onion cell is destroyed, PCSO is converted to sulfenic acid by the action of an enzyme, and a tear component is produced from the sulfenic acid. PCSO is converted to cycloaliyne under heating or alkaline conditions. Thus, PCSO is a relatively unstable substance and is hardly contained in cooked onions that are eaten on a daily basis. Therefore, PCSO has been a component that has received little attention until recently.

  In recent years, PCSO has been reported to have a testosterone-increasing effect, and it is a disease peculiar to women for whom testosterone is effective such as prevention of aging of male function, breast cancer, endometrial cancer, ovarian cancer, thyroid cancer, menopausal dysfunction, etc. It is expected to have an effect on prevention and treatment of cancer (Patent Document 1). However, Patent Document 1 does not report that administration of PCSO actually improved male menopausal syndrome or male function. Furthermore, since PCSO is an unstable substance as described above, a product containing an amount effective for increasing testosterone in adults is expected to be expensive.

  Zinc is the next most essential metal element in the body after iron, and is contained in about 2.3 g in a 70 kg human body. Zinc is involved in the structure formation and maintenance of many enzymes that function in the living body, and is an important element involved in almost systemic functions such as cell division and immune function. In recent years, the problem of zinc deficiency has been raised. Known zinc deficiencies include delayed wound recovery, abnormal reproductive and immune functions, impaired sensory organs (vision, taste, olfaction), skin disorders, metabolic dysfunction, loss of appetite, and growth disorders . On the other hand, due to excessive intake of zinc, gastric disorder, dizziness, nausea etc. are caused by acute zinc poisoning, and continuous excessive intake causes anemia, immune disorders, neurological symptoms, diarrhea, HDL cholesterol decrease due to inhibition of copper and iron absorption Etc. may occur. According to the Ministry of Health, Labor and Welfare's “Japanese dietary intake standards (2010 edition)”, the recommended intake of zinc for men aged 30 to 49 years is an estimated average required amount of 10 mg / day, a recommended amount of 12 mg / day. The limit is 45 mg / day.

Japanese Patent No. 4172488

  The present invention is to provide a composition for preventing or ameliorating symptoms associated with a decrease in male hormones such as male climacteric syndrome, which is low in cost and safe and can be easily taken.

  As a result of searching for various components to solve the above problems, the present inventors have found that a composition containing PCSO and zinc has a remarkable male hormone increase effect and male menopausal syndrome improvement effect as compared with PCSO alone administration. Found to have.

Accordingly, the present invention provides a testosterone enhancer containing S-1-propenyl-L-cysteine sulfoxide and zinc.
The present invention also provides a preventive or ameliorating agent for male climacteric syndrome containing S-1-propenyl-L-cysteine sulfoxide and zinc.
Moreover, this invention provides the prevention or improvement agent of the male function fall containing S-1-propenyl-L-cysteine sulfoxide and zinc.
The present invention further provides a composition containing S-1-propenyl-L-cysteine sulfoxide and zinc in a mass ratio of 1: 4 to 10: 1.

  The composition containing PCSO and zinc of the present invention has a remarkable effect in increasing blood testosterone level and improving male climacteric syndrome, as compared with the case of taking PCSO alone. Further, according to the present invention, since the effective amount of PCSO and zinc can be reduced, side effects due to a large amount of zinc intake can be reduced, and the production cost can be suppressed.

  The present invention provides a composition comprising S-1-propenyl-L-cysteine sulfoxide (PCSO) and zinc. The composition of the present invention has a male hormone (testosterone) increasing action. Therefore, the composition of the present invention can be suitably used for the prevention, amelioration or treatment of various symptoms associated with male hormone lowering. Examples of various symptoms associated with male hormone decline include male climacteric syndrome or LOH syndrome, depressive symptoms, sleep disorders such as insomnia, cognitive function decline, male function decline, infertility due to reduced spermatogenic ability, etc. It is not limited to. According to the composition of the present invention, with a lower dose of PCSO than with PCSO alone, an effect of increasing male hormone equivalent to that of PCSO alone and prevention, improvement or treatment of various symptoms associated with male hormone reduction are obtained. be able to.

  Accordingly, the present invention provides an androgen increasing agent containing PCSO and zinc as active ingredients. The present invention also provides a preventive, ameliorating or treating agent for various symptoms associated with male hormone decline such as male climacteric syndrome or LOH syndrome, male functional decline, depressive symptoms, sleep disorders, cognitive decline, and infertility due to reduced spermatogenic ability. To do. Further, according to the present invention, a male hormone-increasing agent or male climacteric syndrome or LOH syndrome, male function decline, depression, sleep disorder, cognitive function decline, infertility due to reduced spermatogenesis, etc., by combining PCSO and zinc It can be used for the prevention, amelioration, or manufacture of a therapeutic agent for various symptoms associated with hormone lowering. In the following specification, for the male hormone-increasing agent of the present invention and male male menopause syndrome or LOH syndrome, male functional decline, depression, sleep disorders, cognitive decline, infertility due to reduced spermatogenic ability, etc. Agents for preventing, ameliorating or treating various symptoms associated therewith are collectively referred to as agents of the present invention.

  Zinc contained in the agent of the present invention may be in any form of an inorganic salt and an organic salt. Examples of inorganic salts include sulfates, hydrochlorides, nitrates, hydrotalcites and salts with oxides. Examples of organic salts include salts with acetic acid, succinic acid, gluconic acid, ascorbic acid and the like. Is mentioned. Zinc salts can be isolated from organisms containing them, and examples of organisms containing zinc salts include bacteria, microalgae, and yeast.

  PCSO contained in the agent of the present invention can be isolated or purified from a lily family plant. Examples of the liliaceae plant include the genus Allium, and an onion, a leek, a forage, a chives, a leek, a garlic, a ginger, a garlic, a raky, and a leek are preferred. Furthermore, onions, leeks, garlic, and rakkyo are more preferable as raw materials for PCSO used in the present invention because they are inexpensive and contain a large amount of PCSO.

  The above plant contains a large amount of PCSO together with its precursor glutamyl body. However, in these plants, C-S lyase (allylinase), which is an enzyme that converts PCSO into sulfenic acid, is present. Therefore, when plant tissues are destroyed by operations such as extraction and cooking, the action of the enzyme The PCSO in the plant is lost. Therefore, PCSO is hardly contained in the extract of the said plant obtained by the conventional normal method, and the cooked food containing the said plant.

  Therefore, when preparing PCSO from the above-mentioned lily family plant, it is preferable to subject it to an extraction process after heat-treating C-S lyase before cutting the plant. As such a method, a method for preparing cysteine sulfoxide from a genus Allium plant described in Patent Document 1 can be employed. More specifically, a sulfur-containing amino acid contained in the plant is decomposed by heat-treating an uncut genus plant under conditions of a pressure of 1 to 5 atm and a temperature of 40 to 150 ° C. for 5 to 120 minutes. Inactivate C-S lyase. Next, an extract containing an L-cysteine sulfoxide derivative can be obtained by subjecting the heat-treated product of the genus Allium plant to alcohol extraction and concentration under reduced pressure.

  Preferably, the PCSO used in the present invention comprises (i) heating an Allium plant, (ii) treating the heated Allium plant with a γ-glutamyl-binding cleavage enzyme, and then (iii) the resulting enzyme treatment. Can be prepared by subjecting the product to ion exchange chromatography. Below, the detailed procedure of this method is demonstrated.

  The above steps (i) to (iii) are preferably performed under acidic pH conditions in order to prevent alteration of PCSO unless it is required for an enzyme reaction or the like. The preferred pH is pH 5.5 or less, more preferably pH 4.5 or less.

  As the genus Leek plant used as a raw material, bulbs, scallions, chives, leeks are used for edible parts, for example, onions, garlic, and rakyo, and leaves and pseudostems are used for leeks. Moreover, since the hull of the genus Leek plant does not contain PCSO, it is preferable to remove it beforehand.

  In the step (i), the Allium plant is heated. By the heating, the enzyme C-S lyase that degrades PCSO contained in the Allium plant is inactivated. The heating conditions are not particularly limited as long as the C-S lyase can be deactivated without altering the target PCSO, but for example, the pressure is 1 to 5 atm, and the temperature is 40 to 150 ° C. -120 minutes are preferable, pressure is 1-2 atmospheres, temperature is 80-120 degreeC, and 15-40 minutes are more preferable.

  When the interior of an Allium plant is exposed to the air by cutting, crushing, drilling or the like, the contained PCSO is decomposed and the content thereof is reduced. Therefore, the heating is preferably performed on undivided Allium plants. Here, “non-subdivided” leek plants are not processed such as cutting, splitting, crushing, perforation, scratching, etc., or the processing is performed, but the sulfur-containing amino acid is processed by the processing. It means that the content is not greatly reduced, for example, the final yield of sulfur-containing amino acids can achieve 80% or more with respect to intact plants.

  Step (ii) is a step of treating the Allium plant heated in the above step (i) with a γ-glutamyl-binding cleavage enzyme. Since a part of PCSO in the genus Allium plant exists as a glutamyl body, glutamic acid is cleaved from the glutamyl body by enzyme treatment to release PCSO. In order to allow the enzyme reaction to proceed sufficiently, it is preferable to cut, crush, shred, etc. the Allium plant heated in the above step (i) before the enzyme treatment. The subdivided Allium plant is further diluted by about 2 to 20 times with an aqueous liquid such as water, acidic water, or alkaline water. The pH of the aqueous liquid is adjusted to an optimum pH of a γ-glutamyl bond cleaving enzyme used later or a pH in the vicinity thereof.

  Examples of the γ-glutamyl bond cleaving enzyme used for the enzyme treatment include γ-glutaminase, γ-glutamyltransferase, γ-glutamyl transpeptidase, γ-glutamyl peptidase and the like. These enzymes may be extracted from animals, plants, microorganisms or the like, or may be commercially available products. Examples of commercially available products include Amano Enzyme's glutaminase SD-C100S. The conditions for the enzyme treatment may be appropriately set according to the optimal conditions for the enzyme, the type of the genus Leek plant to be used, the site to be used, the size and the subdivision status, and the like. In general, the amount of enzyme added is 0.001 to 1% by mass, preferably 0.01 to 0.1% by mass, based on the total amount of allium plants. The reaction conditions may be an optimum pH of the enzyme and a temperature of 15 to 65 ° C. for about 1 to 24 hours, preferably 35 to 60 ° C. for about 2 to 6 hours. After completion of the enzyme treatment, it is preferable to deactivate the γ-glutamyl bond cleaving enzyme by heating or pH adjustment. If necessary, the reaction product obtained by the enzyme treatment may be filtered, centrifuged, squeezed, etc. to separate the solution containing PCSO. Further, the obtained solution may be concentrated.

  In step (iii), the reaction product obtained by the enzyme treatment in step (ii) is subjected to ion exchange chromatography. Although the ion exchange resin for the said ion exchange chromatography should just be a cation exchange resin, a strong acidic cation exchange resin is preferable and a sulfonic acid type strong acidic cation exchange resin is more preferable. The ion exchange resin can use a commercial item, for example, Diaion (registered trademark) UBK-550, Diaion (registered trademark) SK1B (manufactured by Mitsubishi Chemical Corporation), Amberlite (registered trademark) IR120B, Amber. Light (registered trademark) 200C, Dowex (registered trademark) MSC-1 (The Dow Chemical Company), Duolite C26 (Rohm and Haas), LEWATIT (registered trademark) SP-112 (LANXESS Distribution GmbH), etc. are preferably used. Can be done. The ion exchange chromatography may be performed according to a normal procedure. The eluate containing PCSO obtained by ion exchange chromatography may be used in the present invention as it is, but it is preferable to concentrate or further desalinize it because the purity of PCSO increases. Furthermore, you may perform processes, such as drying, freeze-drying, solidification, liquefaction, granule, or powderization, as needed.

  By the above-described method, a fraction containing a high amount of PCSO can be obtained from a lily family plant. The obtained fraction can be directly contained in the agent of the present invention.

  The content of PCSO in the agent of the present invention is preferably 5 to 100 mg, more preferably 7 to 50 mg, and still more preferably 9 to 25 mg, based on daily intake per adult. When the content of PCSO in the agent of the present invention is less than 5 mg, the desired effect by the agent may not be sufficiently obtained. On the other hand, when the content exceeds 100 mg, an off-flavor or off-flavor may occur. Therefore, it is desirable to apply a treatment to prevent off-flavor or off-flavor to the agent.

  The amount of zinc used in the agent of the present invention is preferably 2 to 20 mg, more preferably 3 to 16 mg, and still more preferably 4 to 12 mg based on the daily intake per adult in terms of zinc element. When the zinc content in the agent of the present invention is less than 2 mg, the desired effect by the agent may not be sufficiently obtained. On the other hand, even if the zinc content is too high, the effect of the agent of the present invention is saturated, which is not economical. Furthermore, an agent having a zinc content exceeding 45 mg may cause side effects due to excessive intake of zinc.

  The mass ratio of PCSO and zinc in the agent of the present invention is preferably PCSO: zinc (in terms of zinc element) = 1: 4 to 10: 1, more preferably 1: 1 to 5: 1. Therefore, as a preferable example of the agent of the present invention, PCSO is contained in an amount of 5 to 100 mg, more preferably 7 to 50 mg, and further preferably 9 to 25 mg per day for an adult, and PCSO: zinc (elemental zinc A composition containing zinc in such an amount that the mass ratio of (converted) is 1: 4 to 10: 1, more preferably 1: 1 to 5: 1. As a further preferred example of the agent of the present invention, PCSO is contained in an amount of 5 to 100 mg, more preferably 7 to 50 mg, more preferably 9 to 25 mg per day for an adult, and zinc is contained per day for an adult. The intake amount is 2 to 20 mg, more preferably 3 to 16 mg, still more preferably 4 to 12 mg, and the mass ratio of PCSO: zinc (in terms of zinc element) is 1: 4 to 10: 1, more preferably 1: 1. A composition that is ˜5: 1.

  When PCSO used in the agent of the present invention is prepared from the above-mentioned liliaceae plant, the chromatographic fraction containing PCSO may contain sulfur-containing amino acids other than PCSO. The agent of the present invention may contain other sulfur-containing amino acids other than PCSO as long as the effect of the agent of the present invention is not inhibited. Examples of the other sulfur-containing amino acids include those other than PCSO such as S-propyl-L-cysteine sulfoxide, S-methyl-L-cysteine sulfoxide (methine), and S-allyl-L-cysteine sulfoxide. Examples thereof include sulfoxides and cycloaliyne. Among these, S-propyl-L-cysteine sulfoxide, S-methyl-L-cysteine sulfoxide and S-allyl-L-cysteine sulfoxide are reported to have a testosterone increasing function in Patent Document 1. It is a substance. Therefore, the agent of the present invention is one or more selected from the group consisting of S-propyl-L-cysteine sulfoxide, S-methyl-L-cysteine sulfoxide and S-allyl-L-cysteine sulfoxide. Can be contained as a further active ingredient. When the agent of the present invention contains a sulfoxide other than PCSO as an active ingredient, PCSO, S-propyl-L-cysteine sulfoxide, S-methyl-L-cysteine sulfoxide and S in the agent of the present invention The mass ratio with respect to the total of allyl-L-cysteine sulfoxide is preferably 10: 1 to 1: 1, more preferably 5: 1 to 2: 1. The total amount of sulfoxides containing PCSO in the agent of the present invention is preferably not more than 120 mg, more preferably not more than 100 mg, based on the daily intake for adults.

  The sulfoxides other than PCSO can be obtained from a fraction containing PCSO obtained by ion exchange chromatography in the above-described procedure for producing PCSO. Alternatively, sulfoxides other than PCSO may be prepared according to the method described in Patent Document 1.

  Furthermore, the agent of the present invention may contain various medicinal components as long as the effect of the agent of the present invention is not inhibited. The medicinal component that can be contained in the agent of the present invention is 1 selected from the group consisting of curcuminoid, capsaicin, tocotrienol, polyphenol, carotenoid, flavonoid, coenzyme Q10, α-lipoic acid, carnitine, anserine, carnosine, EPA and DHA. More than species. The content of the medicinal component in the agent of the present invention can be appropriately determined according to the dosage form, shape, usage and the like of the agent of the present invention, preferably about 0.1 to 50% by mass, more preferably It is about 0.5-30 mass%.

  The agent of the present invention has various symptoms associated with a decrease in androgen such as male hormone increase or male climacteric syndrome or LOH syndrome, decreased male function, depression, sleep disorder, cognitive function, and infertility due to decreased spermatogenic ability. It may be a medicine, food or drink, feed, etc. for prevention, improvement or treatment. The agent of the present invention can be applied to human or non-human mammals. Non-human mammals include pets, domestic animals, and animals raised in breeding facilities.

  The said medicine contains PCSO and zinc as an active ingredient. The pharmaceutical dosage form may be oral or parenteral, but oral is preferred. Examples of oral dosage forms include tablets, capsules, granules, powders, syrups, dry syrups, liquids, suspensions, and the like. The medicament may contain a sulfoxide other than PCSO as an active ingredient in addition to PCSO and zinc, and if necessary, various pharmaceutically acceptable carriers (for example, excipients, Or other additives such as the above-mentioned various medicinal ingredients, various vitamins, herbal medicines, minerals and the like. The medicament can be produced according to a conventional method by combining PCSO and zinc and the above-mentioned carrier and other components. Alternatively, the medicament may be produced by adding the carrier and other components to the composition of the present invention containing PCSO and zinc.

  The above-mentioned food or drink contains PCSO and zinc as active ingredients, and increases male hormones, or male climacteric syndrome or LOH syndrome, decreased male function, depression, sleep disorder, decreased cognitive function, decreased spermatogenic ability Health foods, functional foods, foods for specified health use, foods and drinks for the sick, or livestock, races, with the intention of preventing and improving various symptoms associated with male hormone decline such as infertility It may be feed or pet food for horses, appreciation animals and the like.

  The form of the food and drink and the feed is not particularly limited, and may be solid, semi-solid or liquid, or a tablet, chewable tablet, powder, capsule, granule, drink, gel, syrup, liquid food for enteral enteral nutrition Various forms such as these may be used. The food and drink and feed may contain sulfoxides other than PCSO as an active ingredient in addition to PCSO and zinc. Further, if necessary, other foods and other ingredients (various vitamins, minerals) , Nutritional ingredients, various medicinal ingredients, etc.), or additives commonly used in foods. The food and drink and feed can be produced according to a conventional method by combining PCSO and zinc with the above-mentioned other foodstuffs, other components or additives. Or this food-drinks and feed may be manufactured by adding this other foodstuff, another component, or an additive to the composition of this invention containing PCSO and zinc.

  The content of PCSO and zinc in the above-described agent of the present invention is based on the daily intake. Therefore, depending on the dosage form, shape, usage, etc. of the agent of the present invention, the amount per ingestion unit (for example, a single dose of medicine or a single meal of food or feed) so that the daily intake is an appropriate amount. It is desirable to adjust the addition amount of PCSO and zinc.

  EXAMPLES Next, although an Example is shown and this invention is demonstrated further in detail, this invention is not limited to a following example.

(Production Example 1)
After washing and peeling off 5000 g of onion (North Maple 2000), the whole was heat-treated in a 95 ° C. water bath for 20 minutes without cutting. The onion after heat treatment was crushed using a mixer (manufactured by Oster), and 1 mL of water per 1 g of onion was added and dispersed therein. To the obtained dispersion, glutaminase (glutaminase SD-C100S; manufactured by Amano Enzyme) was added in an amount of 0.025% by mass with respect to the total amount of onion in the solution, and reacted at 60 ° C. for 2 hours. Thereafter, the enzyme was inactivated by heating at 90 ° C. for 15 minutes. The obtained reaction solution was centrifuged at 6,000 rpm for 30 minutes, suction filtered, and then lyophilized to obtain about 500 g of a crude onion extract containing about 3% by mass of a sulfur-containing amino acid.
Distilled water was added to the above onion crude extract to obtain a 30% (w / v) aqueous solution. 1000 mL of this aqueous solution was used as a sample solution and passed through 500 mL of a strongly acidic cation exchange resin (Diaion SK1B, manufactured by Mitsubishi Chemical) regenerated with hydrochloric acid. Next, the sample solution remaining in the column was washed out with 3000 mL of distilled water. Thereafter, 1000 mL of 5% sodium hydroxide solution (pH = 14) was passed through the column to elute the sulfur-containing amino acid adsorbed on the ion exchange resin. Further, 2000 mL of distilled water was added to elute the liquid remaining in the column. The eluate eluted with the sodium hydroxide solution and the eluate eluted with distilled water were combined, concentrated with an evaporator (manufactured by Tokyo Science and Technology), and then desalted to obtain a sulfur-containing amino acid-containing solution. This was freeze-dried to obtain about 40 g of a composition containing sulfur-containing amino acids. As a result of high performance liquid chromatography (HPLC) analysis, the composition contained about 20% by mass of PCSO.

Example 1
A composition containing sulfur-containing amino acid obtained in Production Example 1 (containing 20% by mass of PCSO), zinc (zinc gluconate: manufactured by Tomita Pharmaceutical Co., Ltd.) and polyvinylpyrrolidone (manufactured by BASF) were mixed, and ethanol was added thereto. Thus, grains were produced according to a conventional method by a wet method. After drying the obtained granules, magnesium stearate was added to give granules for tableting, and tableting was performed using a tableting machine, and PCSO and zinc were added in an amount shown in Table 1 in one tablet (300 mg). A containing tablet was prepared.

(Comparative Example 1)
A composition containing sulfur-containing amino acids obtained in Production Example 1 (containing 20% by mass of PCSO) and polyvinylpyrrolidone (manufactured by BASF) are mixed, ethanol is added thereto, and granules are produced according to a conventional method by a wet method did. After drying the obtained granules, magnesium stearate is added to obtain granules for tableting, and tableting is performed using a tableting machine. One tablet (300 mg) contains PCSO in the amount shown in Table 1. Tablets were manufactured.

(Comparative Example 2)
Zinc (zinc gluconate: manufactured by Tomita Pharmaceutical Co., Ltd.) and polyvinylpyrrolidone (manufactured by BASF) were mixed, ethanol was added thereto, and granules were prepared according to a conventional method by a wet method. After drying the obtained granules, magnesium stearate is added to form granules for tableting, and tableting is performed using a tableting machine. One tablet (300 mg) contains zinc in the amount shown in Table 1. Tablets were manufactured.

(Test Example 1)
Seven subjects each of Example 1 or Comparative Example 1 and 4 subjects of Comparative Example 2 (both men over 40 years old) were ingested 6 tablets a day for 2 weeks. Before and after the ingestion period, each subject responded to the Age males' symptoms (AMS) score by Heinemann et al. Shown in Table 2. The difference between the total AMS score before the intake period and the total AMS score after the intake period was taken as the improvement value. The results of Example 1 are shown in Table 3, the results of Comparative Example 1 are shown in Table 4, and the results of Comparative Example 2 are shown in Table 5.

  As is clear from Tables 3 to 5, the AMS score was significantly improved in the group of subjects who took the composition of the present invention of Example 1 as compared to the group of PCSO alone in Comparative Example 1. In the zinc alone intake group of Comparative Example 2, the AMS score did not improve at all, but rather an deteriorated example was observed.

(Test Example 2)
Each of the four subjects (both males over 40 years old) ingested 6 tablets of Example 1 or Comparative Example 1 each day for 2 weeks. Before and after the intake period, the testosterone level in the saliva of each subject was measured using a Testosterone Salivary Immunoassay Kit (Funakoshi). The ratio of the testosterone value after the intake period to the testosterone value before the intake period was defined as the change rate (%). The results of Example 1 are shown in Table 6, and the results of Comparative Example 1 are shown in Table 7.

  As is clear from Tables 6 to 7, the amount of male hormone after ingestion increased in both the subject group who ingested the composition of the present invention of Example 1 and the PCSO alone ingestion group of Comparative Example 1. However, in the group of subjects who ingested the composition of the present invention of Example 1, it was possible to obtain a higher male hormone increase effect with less PCSO intake compared to the PCSO alone intake group of Comparative Example 1. .

Claims (8)

  A preventive or ameliorating agent for male climacteric syndrome comprising S-1-propenyl-L-cysteine sulfoxide and zinc. S-1- propenyl -L- weight ratio of cysteine sulfoxide and zinc is 1: 4 to 10: 1, preventing or ameliorating agent of male menopause syndrome according to claim 1. The agent for preventing or improving male climacteric syndrome according to claim 1 or 2 , comprising 5 to 100 mg of S-1-propenyl-L-cysteine sulfoxide as a daily intake. The agent for preventing or improving male climacteric syndrome according to any one of claims 1 to 3 , comprising 2 to 20 mg of zinc as a daily intake.   A preventive or ameliorating agent for decreased male function, comprising S-1-propenyl-L-cysteine sulfoxide and zinc. The agent for preventing or improving male function deterioration according to claim 5 , wherein the mass ratio of S-1-propenyl-L-cysteine sulfoxide to zinc is 1: 4 to 10: 1. The agent for preventing or improving male function deterioration according to claim 5 or 6, comprising 5 to 100 mg of S-1-propenyl-L-cysteine sulfoxide as a daily intake. The agent for preventing or improving male function deterioration according to any one of claims 5 to 7 , comprising 2 to 20 mg of zinc as a daily intake.